Literature DB >> 24687491

In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.

Jonathan W Betts1, Lynette M Phee2, Michael Hornsey3, Neil Woodford4, David W Wareham5.   

Abstract

We assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurred in vitro against the majority of isolates, with the exception of Serratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P < 0.01) in treating Escherichia coli, Klebsiella pneumoniae, and Enterobacter infections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24687491      PMCID： PMC4068506          DOI： 10.1128/AAC.02449-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  D W Wareham; D C Bean
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Positive correlation between virulence of Pseudomonas aeruginosa mutants in mice and insects.

Authors:  G Jander; L G Rahme; F M Ausubel
Journal:  J Bacteriol       Date:  2000-07       Impact factor: 3.490

3.  Carbapenem-resistant Klebsiella pneumoniae sepsis in corticosteroid receipt mice: tigecycline or colistin monotherapy versus tigecycline/colistin combination.

Authors:  Hayati Demiraslan; Gokcen Dinc; Salman Shaheer Ahmed; Ferhan Elmali; Gokhan Metan; Emine Alp; Mehmet Doganay
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

4.  AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii.

Authors:  Michael Hornsey; Matthew J Ellington; Michel Doumith; Claire P Thomas; Nicola C Gordon; David W Wareham; John Quinn; Karen Lolans; David M Livermore; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2010-06-16       Impact factor: 5.790

Review 5.  Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.

Authors:  Jian Li; Roger L Nation; Robert W Milne; John D Turnidge; Kingsley Coulthard
Journal:  Int J Antimicrob Agents       Date:  2005-01       Impact factor: 5.283

6.  A peptidomics study reveals the impressive antimicrobial peptide arsenal of the wax moth Galleria mellonella.

Authors:  Susan E Brown; Antoinette Howard; Annette B Kasprzak; Karl H Gordon; Peter D East
Journal:  Insect Biochem Mol Biol       Date:  2009-09-26       Impact factor: 4.714

7.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.

Authors:  Karthikeyan K Kumarasamy; Mark A Toleman; Timothy R Walsh; Jay Bagaria; Fafhana Butt; Ravikumar Balakrishnan; Uma Chaudhary; Michel Doumith; Christian G Giske; Seema Irfan; Padma Krishnan; Anil V Kumar; Sunil Maharjan; Shazad Mushtaq; Tabassum Noorie; David L Paterson; Andrew Pearson; Claire Perry; Rachel Pike; Bhargavi Rao; Ujjwayini Ray; Jayanta B Sarma; Madhu Sharma; Elizabeth Sheridan; Mandayam A Thirunarayan; Jane Turton; Supriya Upadhyay; Marina Warner; William Welfare; David M Livermore; Neil Woodford
Journal:  Lancet Infect Dis       Date:  2010-08-10       Impact factor: 25.071

8.  In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates.

Authors:  Roxanne J Owen; Jian Li; Roger L Nation; Denis Spelman
Journal:  J Antimicrob Chemother       Date:  2007-02-08       Impact factor: 5.790

9.  Galleria mellonella as an alternative infection model for Yersinia pseudotuberculosis.

Authors:  Olivia L Champion; Ian A M Cooper; Sarah L James; Donna Ford; Andrey Karlyshev; Brendan W Wren; Melanie Duffield; Petra C F Oyston; Richard W Titball
Journal:  Microbiology       Date:  2009-04-21       Impact factor: 2.777

10.  Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index.

Authors:  K E N Milne; I M Gould
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790
View more
  14 in total

1.  In vitro activity of polymyxin B plus imipenem, meropenem, or tigecycline against KPC-2-producing Enterobacteriaceae with high MICs for these antimicrobials.

Authors:  Natália Barth; Vanessa B Ribeiro; Alexandre P Zavascki
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

2.  In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.

Authors:  Yiying Cai; Tze-Peng Lim; Jocelyn Teo; Suranthran Sasikala; Winnie Lee; Yanjun Hong; Eric Chun Yong Chan; Thean Yen Tan; Thuan-Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.

Authors:  Shawn M Zimmerman; Audrey-Ann J Lafontaine; Carmen M Herrera; Amanda B Mclean; M Stephen Trent
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.

Authors:  Yiying Cai; Tze-Peng Lim; Jocelyn Qi-Min Teo; Suranthran Sasikala; Eric Chun Yong Chan; Yan Jun Hong; Winnie Lee; Thean Yen Tan; Thuan Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

5.  In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii.

Authors:  Wentao Ni; Yifan Wang; Xinqian Ma; Yukun He; Jin Zhao; Jie Guan; Yanjun Li; Zhancheng Gao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-10-06       Impact factor: 5.103

Review 6.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

7.  The pros, cons, and unknowns of search and destroy for carbapenem-resistant enterobacteriaceae.

Authors:  Prashini Moodley; Andrew Whitelaw
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

8.  Serendipitous Discovery of a Highly Active and Selective Resistance-Modifying Agent for Colistin-Resistant Gram-Negative Bacteria.

Authors:  Yuefeng Gao; Somnath Dutta; Xiang Wang
Journal:  ACS Omega       Date:  2022-03-30

9.  The in vitro activity of polymyxin B and tigecycline alone and combination with other antibiotics against carbapenem-resistant Enterobacter cloacae complex isolates, including high-risk clones.

Authors:  Yongxin Zhao; Chunjiang Li; Jisheng Zhang; Yanjun Fu; Kewang Hu; Shanshan Su; Yong Wang; Huiling Li; Xiaoli Zhang
Journal:  Ann Transl Med       Date:  2019-12

10.  Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.

Authors:  Phillip J Bergen; Zackery P Bulman; Cornelia B Landersdorfer; Nicholas Smith; Justin R Lenhard; Jürgen B Bulitta; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  Infect Dis Ther       Date:  2015-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.